151 related articles for article (PubMed ID: 38794260)
1. A Two-Way Proposal for the Determination of Bioequivalence for Narrow Therapeutic Index Drugs in the European Union.
Paixao P; Garcia Arieta A; Silva N; Petric Z; Bonelli M; Morais JAG; Blake K; Gouveia LF
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794260
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union.
Paixão P; Silva N; Guerreiro RB; Blake K; Bonelli M; Morais JAG; García-Arieta A; Gouveia LF
Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365166
[TBL] [Abstract][Full Text] [Related]
3. A Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union.
Paixão P; Guerreiro RB; Silva N; Blake K; Bonelli M; Morais JAG; Garcia Arieta A; Gouveia LF
Clin Pharmacol Ther; 2022 Feb; 111(2):470-476. PubMed ID: 34657284
[TBL] [Abstract][Full Text] [Related]
4. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
7. Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology.
Lechat P
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):777-787. PubMed ID: 35986193
[TBL] [Abstract][Full Text] [Related]
8. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
Tothfalusi L; Endrenyi L; Arieta AG
Clin Pharmacokinet; 2009; 48(11):725-43. PubMed ID: 19817502
[TBL] [Abstract][Full Text] [Related]
10. Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burden.
Endrenyi L; Tothfalusi L
J Pharm Pharm Sci; 2013; 16(5):676-82. PubMed ID: 24393551
[TBL] [Abstract][Full Text] [Related]
11. An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
Tothfalusi L; Endrenyi L
AAPS J; 2016 Mar; 18(2):476-89. PubMed ID: 26831249
[TBL] [Abstract][Full Text] [Related]
12. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
Odi R; Franco V; Perucca E; Bialer M
Epilepsia; 2021 Feb; 62(2):285-302. PubMed ID: 33426641
[TBL] [Abstract][Full Text] [Related]
13. Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability.
Lechat P; Kir F; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2023 Nov; 79(11):1565-1578. PubMed ID: 37737912
[TBL] [Abstract][Full Text] [Related]
14. Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study.
Wang L; Di Y; Guo T; Ming JE; Kong F; Yin H; Zhang L; Xie F; Yang N; Ping C; Li Y; Hou J
Adv Ther; 2020 Jun; 37(6):2696-2709. PubMed ID: 32418143
[TBL] [Abstract][Full Text] [Related]
15. Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.
Hammami MM; De Padua SJS; Hussein R; Al Gaai E; Khodr NA; Al-Swayeh R; Alvi SN; Binhashim N
BMC Pharmacol Toxicol; 2017 Dec; 18(1):78. PubMed ID: 29216899
[TBL] [Abstract][Full Text] [Related]
16. Meeting Regulatory Requirements for Drugs with a Narrow Therapeutic Index: Bioequivalence Studies of Generic Once-Daily Tacrolimus.
Gantar K; Škerget K; Mochkin I; Bajc A
Drug Healthc Patient Saf; 2020; 12():151-160. PubMed ID: 32982466
[TBL] [Abstract][Full Text] [Related]
17. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
Le Corre P
Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
19. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax
Zhang Y; Chen X; Tang Y; Lu Y; Guo L; Zhong D
Drug Des Devel Ther; 2017; 11():2109-2119. PubMed ID: 28744102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
